Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET-Guided surgery could extend life for aggressive brain cancer patients

NCT ID NCT07567196

Disease control Sponsor: Universita degli Studi di Genova Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether using a special PET scan before surgery helps surgeons remove more of a high-grade glioma (a fast-growing brain tumor) safely. About 100 adults with newly diagnosed tumors will get both a PET and MRI scan before surgery. After surgery, doctors will check if removing extra tissue seen on PET improves how long patients live without the cancer growing. The goal is to find a better way to treat these aggressive tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adult patients diagnosed with high-grade glioma, located supratentorially and eligible for surgical resection. Inclusion criteria consist of age ≥18 years, have a high-grade glioma (WHO grade III/IV) diagnosed on MRI as assessed by the neurosurgeon, and provide written informed consent. Exclusion criteria include tumors located in the cerebellum, brainstem, or midline. Patients with medical conditions precluding MRI, such as those with a pacemaker, are not eligible. Other exclusion criteria include the inability to provide written informed consent, secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma, and a second primary malignancy within the past five years.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥18 years * high-grade glioma (WHO grade III/IV) diagnosed on MRI * provide written informed consent Exclusion Criteria: * tumors located in the cerebellum, brainstem, or midline. * Patients with medical conditions precluding MRI * inability to provide written informed consent * secondary high-grade gliomas resulting from malignant transformation of a low-grade glioma * other primary malignancy within the past five years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioma glioblastoma multiforme are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glioma glioblastoma multiforme Glioma surgery Glioma, high grade Positron-emission tomography(PET)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Città della Salute e della Scienza

    RECRUITING

    Torino, Turin, 10126, Italy

  • IRCCS Azienda Ospedaliera Metropolitana

    RECRUITING

    Genova, 16100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.